VLA 0.00% $1.75 viralytics limited

IDO1/Keytruda combo trial fails in melanoma, page-5

  1. 3,253 Posts.
    lightbulb Created with Sketch. 26
    Hi,
    I think Merck will end up needing to raise their offer.
    There has been enough shares traded to form a block for a more competitive offer.
    Daveys post has just reinforced the fact Cavatak is the leader in the field.
    Lepu could change there mind as well if they smell a dollar more.
    All IMO.
    Aloha.
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.